医学
利拉鲁肽
内科学
糖尿病
2型糖尿病
心脏病学
内分泌学
作者
Steven P. Marso,Gilbert H. Daniels,Kirstine Brown‐Frandsen,Peter Lommer Kristensen,Johannes F.E. Mann,Michael A. Nauck,Steven E. Nissen,Stuart Pocock,Neil R Poulter,Lasse Steen Ravn,William M. Steinberg,Mette Stockner,Bernard Zinman,Richard M. Bergenstal,John B. Buse
标识
DOI：10.1056/nejmoa1603827
摘要
In the time-to-event analysis, the rate of the first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke among patients with type 2 diabetes mellitus was lower with liraglutide than with placebo. (Funded by Novo Nordisk and the National Institutes of Health; LEADER ClinicalTrials.gov number, NCT01179048.).
科研通智能强力驱动
Strongly Powered by AbleSci AI
PDF的下载单位、IP信息已删除
(2025-6-4)
皖公网安备34019202002308
